Genetic Signatures Limited (GSS.AX)
Genetic Signatures Limited operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Newtown, NSW, AU. The stock last traded at $0.06, up 0.00% on the session, giving a market capitalisation of $13.2M. Its beta of 0.52 implies it has historically moved less than the broad market.
Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of real-time Polymerase Chain Reaction (PCR)-based products, sold under the EasyScreen brand, for the identification of infectious diseases. Moreover, it offers its proprietary MDx 3Base platform technology, enabling hospitals and pathology laboratories to conduct comprehensive screenings for diverse infectious pathogens. Its offerings also encompass detection kits tailored for conditions such as gastrointestinal ailments, respiratory illnesses, sexual health concerns, antimicrobial resistance, meningitis, and tropical diseases. Founded in 2001, the firm is headquartered in Newtown, Australia.
Genetic Signatures Limited is most often compared with the following Healthcare names: